• Cryptosporidiosis is a severe public health issue, causing acute diarrhea, malnutrition, developmental delays, and high child mortality, particularly in sub-Saharan Africa, South America, and Asia. Responsible for 7.5 million cases and 200,000 child deaths annually, the disease primarily affects children under five. 

• Existing treatment, nitazoxanide, is largely ineffective for malnourished or immunocompromised patients, leaving a critical need for better solutions. 

• The Cryptosporidiosis Therapeutics Advocacy Group (CTAG) is pushing for its inclusion in the WHO’s list of neglected tropical diseases (NTDs), which would drive global awareness, funding, and collaboration. 

• Such recognition could enhance global awareness, increase funding, and foster collaboration, thereby catalyzing research efforts, expediting the development of treatments and vaccines, and encouraging pharmaceutical companies to invest through incentives like FDA priority review vouchers. 

• Promising new treatments are currently in clinical trials, offering hope for effective solutions. Global action is essential to reduce cryptosporidiosis’s devastating impact on vulnerable populations, especially young children in low-income regions.

Click here to read more.